Magnasense AB develops and commercializes diagnostic tests for monitoring and optimizing the dosage of biological drugs. The company develops a testing platform for oral health, therapeutic drug monitoring, and infectious diseases. It develops Veritope technology used to optimize the dosage of biological drugs to patients; and the MagniaReader platform. The company was formerly known as AegirBio AB (publ) and changed its name to Magnasense AB in July 2024. Magnasense AB was incorporated in 2019 and is based in Lund, Sweden.
Frequently asked questions
What sector does Magnasense AB (MAGNA) operate in?
Magnasense AB belongs to the Other sector and operates in the Software - Infrastructure industry.
What is Magnasense AB (MAGNA) current stock price?
As of the latest data, Magnasense AB stock price is SEK 12.30, with a previous close of SEK 12.30.
What is Magnasense AB (MAGNA) current market capitalization?
Magnasense AB market cap is approximately 32.55 billion.
What is Magnasense AB (MAGNA) Earnings Per Share (EPS)?
The trailing EPS is -SEK 0.56.
Does Magnasense AB (MAGNA) pay dividends?
No. Magnasense AB does not pay a dividend.
What is Magnasense AB (MAGNA) beta (volatility) score?
Magnasense AB has a beta of 2.167, indicating very high volatility compared to the market.